Clinical Trials Public Health

Home  Company Public Health Directives Public Health Information for Students Public Health Links Public Health Internships PHD International Training Priorities Openings Public Health Books Clinical Trials Public Health My Files Guest Book

Clinical Trials. A Public Health Need?

Food and Drug Administration Modernization Act of 1997 (FDAMA) requires the Department of Health and Human Services (DHHS) to determine the feasibility of including device clinical trials within the scope of the PHS data bank established and a establish a database for all clinical trials and clinical trial data.

The data bank established is limited to pharmaceutical clinical trials and is meant to be used by prospective patients, health care providers, researchers, and the general public. This provision requires sponsors of federally and privately funded studies of new drugs to treat serious or life-threatening diseases and conditions to submit information on the purpose of the experimental drug in the study, eligibility criteria, study sites, and a contact for patients wishing to enroll. FDA is collaborating with NIH to begin operation of the data bank in 2000.

Clinical Trials: In the US and Internationally

Clinical research has always been a global activity. It is through clinical trials that the world receives it life saving medications and treatments.

Public Health Need for Access to Information – The reality is that research depends upon patients, their active participation, their treatment, and the care because in their need or just desire to help, we are all saved. Ethical standards such as the Nuremberg Code, Declaration of Helsinki, and the Belmont Report have begun the process of insuring the protection of patients. But, it is the institutional review board (IRB) that safeguards patients today. PHD International combines efforts with Sephmer Sciences to help develop IRBs in the United States and internationally.0

Ethical Issues Reviewed by IRB's


IRB's have several criteria by which they determine approval of research:

1. Risks to subjects are minimized

2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may be expected to result

3. Selection of subjects is fair and equitable

4. Informed consent will be sought from each prospective subject or the subject's legally authorized representative

5. Informed consent will be appropriately documented

6. The research plan makes provision for monitoring the data collected to ensure the safety of the subjects, where appropriate

7. Where appropriate, provisions will be made for the protection of the privacy of the subjects. Confidentiality of the data will be maintained

8. Vulnerable populations will be protected from coercion or undue influence

(from Code of Federal Regulations 56.111)

The Nuremberg Code


  1. The voluntary consent of the human subject is absolutely essential. This means that the person involved should have legal capacity to give consent; should be so situated as to be able to exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, over-reaching, or other ulterior form of constraint or coercion; and should have sufficient knowledge and comprehension of the elements of the subject matter involved as to enable him to make an understanding and enlightened decision. This latter element requires that before the acceptance of an affirmative decision by the experimental subject there should be made known to him the nature, duration, and purpose of the experiment; the method and means by which it is to be conducted; all inconveniences and hazards reasonable to be expected; and the effects upon his health or person which may possibly come from his participation in the experiment.

    The duty and responsibility for ascertaining the quality of the consent rests upon each individual who initiates, directs or engages in the experiment. It is a personal duty and responsibility which may not be delegated to another with impunity.

  2. The experiment should be such as to yield fruitful results for the good of society, unprocurable by other methods or means of study, and not random and unnecessary in nature.

  3. The experiment should be so designed and based on the results of animal experimentation and a knowledge of the natural history of the disease or other problem under study that the anticipated results will justify the performance of the experiment.

  4. The experiment should be so conducted as to avoid all unnecessary physical and mental suffering and injury.

  5. No experiment should be conducted where there is an a priori reason to believe that death or disabling injury will occur; except, perhaps, in those experiments where the experimental physicians also serve as subjects.

  6. The degree of risk to be taken should never exceed that determined by the humanitarian importance of the problem to be solved by the experiment.

  7. Proper preparations should be made and adequate facilities provided to protect the experimental subject against even remote possibilities of injury, disability, or death.

  8. The experiment should be conducted only by scientifically qualified persons. The highest degree of skill and care should be required through all stages of the experiment of those who conduct or engage in the experiment.

  9. During the course of the experiment the human subject should be at liberty to bring the experiment to an end if he has reached the physical or mental state where continuation of the experiment seems to him to be impossible.

  10. During the course of the experiment the scientist in charge must be prepared to terminate the experiment at any stage, if he has probable cause to believe, in the exercise of the good faith, superior skill and careful judgment required of him that a continuation of the experiment is likely to result in injury, disability, or death to the experimental subject.

Reprinted from Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10, Vol. 2, pp. 181-182.. Washington, D.C.: U.S. Government Printing Office, 1949.